While most in the industry are focusing on building exceptional AI models to accelerate drug discovery, I had the privilege of presenting at PEGS Europe on a topic that’s still overlooked but just as critical: overcoming barriers to AI adoption. A thread 🧵 #MLOps #drugdiscovery

ENPICOM is heading to #AntibodyEng! 🎤 Don't miss our talk on breaking barriers to AI adoption in biologics discovery. Monday, 1:15 PM ☕ Visit booth 208 to discuss faster #antibodydiscovery workflows, #AI integration, and #MLOps.

Despite significant investment, many companies face challenges integrating #AI into biologics discovery. Bridging the gap requires rethinking data strategies and building AI-ready environments. Learn more in our latest blog: eu1.hubs.ly/H0fj35-0 #biologicsdiscovery

🌟 Kicking off #AntibodyEng today! 🎤 Don’t miss Néstor Vázquez Bernat, PhD, at 1:15 PM, sharing insights on breaking AI barriers in biologics discovery. 🍬 Stop by booth 208 for a chat on biologics optimization workflows—and grab some Dutch treats! #AI #ML #biologics

The final day of #AntibodyEng is here, but there’s still time to connect! ✨ Swing by booth 208 to meet the ENPICOM team and chat about #biologics discovery, #AI integration, and innovative workflows. See you there!

Seeing the bigger picture in #antibodydiscovery means looking beyond linear sequences. 🧬 High-throughput structural modeling provides critical insights into exposed liabilities, enabling a streamlined path to the most promising therapeutics. Learn more: eu1.hubs.ly/H0fwKrq0

As AI scales across the industry, it brings challenges around the consistency and reproducibility of #ML models essential for the scientific method. This is where #MLOps makes all the difference. Learn more in our blog: eu1.hubs.ly/H0fDGZB0

Not all exposed liabilities in antibody sequences carry the same weight. With region multipliers, you can easily adjust the importance of exposed liabilities in both the Framework and Complementarity-Determining Regions. Learn more: eu1.hubs.ly/H0fDGT70

Rise and shine, San Diego! ☀️ The #BioLogicSummit starts today, and we’re excited to dive into conversations about accessible data, advanced analyses, and AI innovation. Visit us at booth 213—let’s connect! #AI #ML #biologics #conference

Missed our talk at #AntibodyEng? Watch the recording here: eu1.hubs.ly/H0fPkBw0 Discover how managing the entire ML model lifecycle is essential for effective therapeutic research and maximizing AI investment. #AI #ML #drugdiscovery #MLOps

Overcoming the barriers to AI integration is crucial to unlocking its full potential in biologics discovery and engineering. In our recent blog, we explore the key steps to achieving AI readiness: eu1.hubs.ly/H0fPkNN0 #AI #DrugDiscovery #PharmaInnovation #AIAdoption

What is MLOps, and why should biologics discovery companies pay attention? Organizations that master MLOps will unlock faster iteration cycles, greater scalability, and a smoother path to regulatory approval. Learn more in our blog: eu1.hubs.ly/H0g6TWD0

Realizing the transformative potential of #AI requires the ability to systematically test, improve, and deploy ML models at scale. Discover how a unified platform can streamline AI workflows in biologics discovery, from model training to deployment. eu1.hubs.ly/H0g6V3l0

🌟 We’re heading to #PEGSEurope in Lisbon! 📆 Date: November 11 - 13 | 📍Booth 313 Come chat with us about your biologics discovery workflows and learn how ENPICOM can accelerate AI adoption.

Innovation in biopharma doesn’t happen by accident; it’s a compound effect of data discipline, cross-functional culture, and a willingness to take real technical risk. Learn more in the premier episode of #ModelsnMolecules: eu1.hubs.ly/H0pn9Mw0 #AIinpharma

We've all seen promising tech fail to deliver. What do we learn from it? In our recent episode of Models & Molecules, René Hoet gives a candid take on navigating the hype cycle: eu1.hubs.ly/H0pncX_0 #ModelsnMolecules #drugdiscovery